CA Patent

CA3225293A1 — Solid state forms

Assigned to Amgen Inc · Expires 2020-11-26 · 5y expired

What this patent protects

The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxypheny1)-1-(4-methy1-2-(2-propany1)-3-pyridiny1)-4-((2S)-2-methyl-4-(2-propenoy1)-1-piperazinyl)pyrido[2,3-dlpyrimidin-2(1H)-one, including several anhydrous,hydrate and solvate forms,…

USPTO Abstract

The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxypheny1)-1-(4-methy1-2-(2-propany1)-3-pyridiny1)-4-((2S)-2-methyl-4-(2-propenoy1)-1-piperazinyl)pyrido[2,3-dlpyrimidin-2(1H)-one, including several anhydrous,hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Drugs covered by this patent

Patent Metadata

Patent number
CA3225293A1
Jurisdiction
CA
Classification
—
Expires
2020-11-26
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.